Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: Daegu and Gyeongbuk Statin Registry
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To date, prospective data are limited on efficacy and safety profiles of statin therapy in Korean hypercholesterolemic patients. Hence, the aim of this study was to evaluate the practice patterns of statin therapy and its efficacy and safety through the prospective Daegu and Gyeongbuk statin registry. Methods: Statin naïve patients who were prescribed statins according to the criteria of Korean Guidelines for Management of Dyslipidemia were enrolled. Clinical and laboratory evaluations were performed at baseline and at week 8, where the efficacy was assessed with the same guidelines. Results: Of 908 patients, atorvastatin and rosuvastatin were most frequently prescribed statins (63.1% and 29.3%, respectively). High intensity statins (atorvastatin 40 mg or rosuvastatin 20 mg) were prescribed in 24.7% of all patients and in 79.5% of high and very high risk groups. The total and low density lipoprotein (LDL) cholesterol levels decreased from 203.7 ± 43.0 to 140.6 ± 28.6 mg/dL and 134.4 ± 35.7 to 79.5 ± 21.3 mg/dL, respectively. The achievement rate of the LDL target goal was 98.6% in low risk, 95.0% in moderate risk, 88.1% in high risk, and 42.1% in very high risk patients (59.7% in overall). There was no significant difference in the efficacy between atorvastatin and rosuvastatin. Adverse events were observed in 12.0% of patients and led to 1.4% of treatment cessation. Conclusions: The efficacy of the usual starting dose of statins in daily practice was relatively insufficient for Korean hypercholesterolemic patients with high or very high risks. Short-term adverse events of statin therapy were not common in Korean patients with a low discontinuation rate.
Abstract
Background/Aims: To date, prospective data are limited on efficacy and safety profiles of statin therapy in Korean hypercholesterolemic patients. Hence, the aim of this study was to evaluate the practice patterns of statin therapy and its efficacy and safety through the prospective Daegu and Gyeongbuk statin registry. Methods: Statin naïve patients who were prescribed statins according to the criteria of Korean Guidelines for Management of Dyslipidemia were enrolled. Clinical and laboratory evaluations were performed at baseline and at week 8, where the efficacy was assessed with the same guidelines. Results: Of 908 patients, atorvastatin and rosuvastatin were most frequently prescribed statins (63.1% and 29.3%, respectively). High intensity statins (atorvastatin 40 mg or rosuvastatin 20 mg) were prescribed in 24.7% of all patients and in 79.5% of high and very high risk groups. The total and low density lipoprotein (LDL) cholesterol levels decreased from 203.7 ± 43.0 to 140.6 ± 28.6 mg/dL and 134.4 ± 35.7 to 79.5 ± 21.3 mg/dL, respectively. The achievement rate of the LDL target goal was 98.6% in low risk, 95.0% in moderate risk, 88.1% in high risk, and 42.1% in very high risk patients (59.7% in overall). There was no significant difference in the efficacy between atorvastatin and rosuvastatin. Adverse events were observed in 12.0% of patients and led to 1.4% of treatment cessation. Conclusions: The efficacy of the usual starting dose of statins in daily practice was relatively insufficient for Korean hypercholesterolemic patients with high or very high risks. Short-term adverse events of statin therapy were not common in Korean patients with a low discontinuation rate.
참고문헌 (29)
- Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
- Gerber RT, "Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score", Cardiovasc Revasc Med, 12, pp.220~227 (2011)
- 문경준, "Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease", Journal of Clinical Neurology, 10(2), pp.140~147 (2014), 대한신경과학회[DOI]
- Gaw A, "The care gap : underuse of statin therapy in the elderly", Int J Clin Pract, 58, pp.777~785 (2004)
- LaRosa JC, "Effect of statins on risk of coronary disease : a meta-analysis of randomized controlled trials", JAMA, 282, pp.2340~2346 (1999)
- Stancu C, "Statins : mechanism of action and effects", J Cell Mol Med, 5, pp.378~387 (2001)
- Thom T, "Heart disease and stroke statistics : 2006 update : a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee", Circulation, 113, pp.e85~e151 (2006)
- Ko DT, "Lipid-lowering therapy with statins in high-risk elderly patients : the treatment-risk paradox", JAMA, 291, pp.1864~1870 (2004)
- Bellosta S, "Safety of statins : focus on clinical pharmacokinetics and drug interactions", Circulation, 109(23 Suppl 1), pp.III50~III57 (2004)
- Jones PH, "Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)", Am J Cardiol, 92, pp.152~160 (2003)
- European Association for Cardiovascular Prevention & Rehabilitation, "ESC", EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), 2011, pp.32, 1769~1818
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63(25 Pt B)[DOI]
- Mancini GB, "Diagnosis, prevention, and management of statin adverse effects and intolerance : Canadian Consensus Working Group update(2016)", Can J Cardiol, 32(7 Suppl), pp.S35~S65 (2016)
- Bays H, "An assessment by the Statin Liver Safety Task Force: 2014 update", J Clin Lipidol, 8(3 Suppl), pp.S47~S57 (2014)
- Downs JR, "Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS", TexCAPS. Air Force, JAMA, pp.1998, 279[DOI]
- "West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials", Lancet, 348, pp.1339~1342 (1996)
- Jacobson TA, "National lipid association recommendations for patient-centered management of dyslipidemia: part 1. Full report", J Clin Lipidol, 9, pp.129~169 (2015)
- Jellinger PS, "American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease", Endocr Pract, 23(Suppl 2), pp.1~87 (2017)
- Wang P, "Statin dose in Asians : is pharmacogenetics relevant", Pharmacogenomics, 12, pp.1605~1615 (2011)
- Martineau P, "Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study", Atherosclerosis, 191, pp.135~146 (2007)
- Park JE, "Lipid-lowering treatment in hypercholesterolaemic patients : the CEPHEUS Pan-Asian survey", Eur J Prev Cardiol, 19, pp.781~794 (2012)
- American Diabetes Association, "Standards of medical care in diabetes: 2016", Diabetes Care, 39(Suppl 1), pp.s60~s71 (2016)
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report", Circulation, 106, pp.3143~3421 (2002)
- Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
- 조윤경, "Comparison of Ezetimibe", Simvastatin 10, Korean Circulation Journal, pp.2011, 41(3)[DOI]
- 남창욱, "Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study", The Korean Journal of Internal Medicine, 34(6), pp.1252~1262 (2019), 대한내과학회[DOI]
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Ridker PM, "The JUPITER trial : results, controversies, and implications for prevention", Circ Cardiovasc Qual Outcomes, 2, pp.279~285 (2009)
- Ogawa H, "Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2diabetes patients (LISTEN) study", Circ J, 78, pp.2512~2515 (2014)